Diabetes Center, Institute of Metabolism and Endocrinology, The Second Xiangya Hospital and Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, Changsha, China.
J Diabetes. 2014 Jan;6(1):21-9. doi: 10.1111/1753-0407.12063. Epub 2013 Jun 19.
Dipeptidyl peptidase (DPP)-4 inhibitors are a new class of antidiabetic agents that reduce blood glucose by preventing the degradation of the endogenous incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Protection by DPP-4 inhibitors of β-cell function has been demonstrated in patients with type 2 diabetes. Because DPP-4 is an enzyme widely expressed in humans, DPP-4 inhibitors are speculated to be multitarget agents. However, other potential therapeutic benefits of DPP-4 inhibitors remain unknown. Recently, some therapeutic effects of DPP-4 inhibitors, such as immune regulation, cardiovascular protection, and anti-inflammatory effects, have been observed. This article provides a systematic and comprehensive review of current research into the newly found effects and mechanism of action of DPP-4 inhibitors in a therapeutic context.
二肽基肽酶-4（DPP-4）抑制剂是一类新型的抗糖尿病药物，通过抑制内源性肠促胰岛素激素胰高血糖素样肽-1 和葡萄糖依赖性胰岛素释放多肽的降解来降低血糖。在 2 型糖尿病患者中已经证明 DPP-4 抑制剂对 β 细胞功能具有保护作用。由于 DPP-4 在人体中广泛表达，因此推测 DPP-4 抑制剂是一种多靶点药物。然而，DPP-4 抑制剂的其他潜在治疗益处尚不清楚。最近，已经观察到 DPP-4 抑制剂的一些治疗作用，如免疫调节、心血管保护和抗炎作用。本文对 DPP-4 抑制剂在治疗中的新发现的作用和作用机制进行了系统和全面的综述。
